Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Scoping
Process STA Standard
ID number 6369

Provisional Schedule

Committee meeting: 1 05 February 2025
Assessment report sent for information 16 July 2025

Project Team

Project lead Vonda Murray

Email enquiries

External Assessment Group Bristol Technology Assessment Group, University of Bristol


Companies sponsors Biogen (natalizumab)
  Sandoz (Tyruko (natalizumab biosimilar))
Others Department of Health and Social Care
  Health Technology Wales (HTW)
  NHS England
  Welsh Government
Patient carer groups Brain and Spine Foundation
  Brain Charity
  Multiple Sclerosis Society
  Multiple Sclerosis Trust
  Neurological Alliance
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of British Neurologists
  British Association of Neuroscience Nurses
  British Geriatrics Society
  British Neuropathological Society
  British Society for Blood and Marrow Transplantation
  British Society of Rehabilitation Medicine
  Chartered Society of Physiotherapy
  Institute of Neurology
  London MS-AHSCT Collaborative Group
  National Neuroscience Advisory Group
  Primary Care and Community Neurology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Occupational Therapists
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Therapists in MS
  UK Clinical Pharmacy Association
  UK Multiple Sclerosis Specialist Nurse Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Amarox (fingolimod)
  Bayer (interferon beta-1a, interferon beta-1b)
  Biocon Pharma (fingolimod)
  Biogen Idec (interferon beta-1a)
  Dr. Reddy's Laboratories (fingolimod)
  Glenmark Pharmaceuticals (fingolimod)
  Janssen-Cilag (ponesimod)
  Merck Serono (cladribine, interferon beta-1a)
  Mylan (fingolimod, glatiramer acetate, teriflunomide)
  Novartis Pharmaceuticals (fingolimod, interferon beta-1a, interferon beta-1b, ofatumumab)
  Roche Products (ocrelizumab)
  Sandoz (fingolimod)
  Sanofi Genzyme (alemtuzumab)
  Sun Pharma (fingolimod)
  Teva (fingolimod, glatiramer acetate)
  Tillomed Laboratories (fingolimod)
  Zenvita (fingolimod)
Evidence review group Bristol Technology Assessment Group, University of Bristol
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Multiple Sclerosis Society Wales
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research UK
  Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
  Cochrane UK
  Genomics England
  MRC Clinical Trials Unit


Key events during the development of the guidance:

Date Update
03 May 2024 Invitation to participate
19 January 2024 - 16 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
19 January 2024 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual